Showing 17,961 - 17,980 results of 29,839 for search '(( 5 ((step decrease) OR (nn decrease)) ) OR ( 50 ((mean decrease) OR (a decrease)) ))', query time: 1.07s Refine Results
  1. 17961
  2. 17962
  3. 17963
  4. 17964
  5. 17965
  6. 17966

    Characteristics of Physician Outflow from Disaster Areas following the Great East Japan Earthquake by Saori Kashima (126020)

    Published 2017
    “…<div><p>Objective</p><p>The shortage of physicians after a major disaster is a crucial issue. We aimed to evaluate the characteristics of physicians who left affected areas following the accident at Fukushima Daiichi Nuclear Power Plant caused by the Great East Japan Earthquake on March 11, 2011.…”
  7. 17967
  8. 17968
  9. 17969
  10. 17970
  11. 17971
  12. 17972
  13. 17973
  14. 17974

    Longitudinal study on changes in COVID-19 vaccination intentions in Benin and Senegal: Insights from Generalized Estimating Equations (GEE) by Ibrahima Gaye (8462562)

    Published 2025
    “…Vaccination intent increased more significantly in Senegal (+12.5 points, <i>p</i> = .000) than in Benin (+5.0 points, <i>p</i> = .089). There was a statistically significant increase in vaccine intent among women (+19.9 points) and individuals under 25 (+15.6 points) in Senegal, whereas in Benin, younger respondents showed a decrease (−11.5 points). …”
  15. 17975
  16. 17976
  17. 17977
  18. 17978

    Pituitary Adenylate Cyclase Activating Peptide (1-38) and its analog (Acetyl-[Ala15, Ala20] PACAP 38-polyamide) reverse methacholine airway hyperresponsiveness in rats by Mounira Tlili (12847046)

    Published 2022
    “…PACAP38 analog prevents effectively bronchial smooth muscle layer thickness, mucus hypersecretion and lumen decrease. Therefore, it may constitute a potent therapeutic bronchodilator.…”
  19. 17979
  20. 17980

    Effect of mini-dose ready-to-use liquid glucagon on preventing exercise-associated hypoglycemia in adults with type 1 diabetes by Ronnie Aronson (3705877)

    Published 2023
    “…</p> <p>Research Design and Methods</p> <p>Individuals initially participated in the in-clinic training phase for which they were randomized to a crossover design: 150 µg glucagon (treatment arm A) or placebo (arm B) subcutaneously, immediately before exercise, plus 50% reduction in continuous subcutaneous insulin infusion (CSII) basal delivery rate. …”